**REGISTERED COMPANY NUMBER: CE004367 (England and Wales) REGISTERED CHARITY NUMBER: 1163211**
## **Report of the Trustees and**
**Unaudited Financial Statements for the Year Ended 31st December 2020**
**for**
**European Parkinson's Disease Association**
A4G LLP Kings Lodge London Road West Kingsdown Sevenoaks Kent TN15 6AR
**European Parkinson's Disease Association**
## **Contents of the Financial Statements for the Year Ended 31st December 2020**
||**Page**|
|---|---|
|**Report of the Trustees**|1 to 5|
|**Independent Examiner's Report**|6|
|**Statement of Financial Activities**|7|
|**Statement of Financial Position**|8|
|**Statement of Cash Flows**|9|
|**Notes to the Statement of Cash Flows**|10|
|**Notes to the Financial Statements**|11 to 19|
|**Detailed Statement of Financial Activities**|20 to 22|
**European Parkinson's Disease Association**
## **Report of the Trustees**
## **for the Year Ended 31st December 2020**
The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31st December 2020. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).
## **Introduction**
2020 has been a very difficult year for the whole world, and in particular organisations working in the non-profit sector - including many EPDA member organisations - have been hit particularly hard by the COVID-19 pandemic. In spite of this, the EPDA has been able to adapt to the 'new normal' and achieve a series of accomplishments that, we believe, allow us to lay the foundations for a positive post-COVID-19 outlook.
In the past 12 months, we completed the process to substantially improve the EPDA's internal governance - reforming our Statutes (with the help and collaboration of our Members) and striving for increased transparency and democracy. We also acquired new member organisations and started a process to improve and boost the two-way communication with our members - the first step being an important survey to better understand our members' opinions, needs and challenges.
We have continued to develop our relationships with the treatment industry, securing a record number of funding partners going into 2021 and engaging in a number of win-win partnered projects that will benefit the Parkinson's community - in many cases leading to better treatment options for people living with the condition.
We continued the roll-out of our EU advocacy strategy and developed new EPDA strategic projects that are set to be carried out over the next four years.
Last but not least, we produced and delivered some impressive online resources (developed both independently and in partnership with the treatment industry) to provide support to the Parkinson's community during the COVID-19 lockdown periods.
The EPDA Team would like to thank the EPDA Board members for contributing with their knowledge, expertise and constant commitment to the positive results of the projects and activities detailed below.
## **Governance**
## **Statutes:**
o Amendments proposed and discussed in late 2019, voted by Members in early 2020 o Most proposed amends approved by a majority of the Members o Statutes changes ratified by the AGM in September 2020
o Amendment procedure to be finalised in 2021
## **Board:**
o A new President and Vice-President elected o Three new full Board members (former observers) elected by the AGM o Three new Board observers appointed in 2020
## **Results**
o Increased transparency and democracy o Smoother decision-making process and internal functioning o Improved expertise and representation in the Board
## **EPDA strategy**
EPDA strategy reviewed by the EPDA Board at the end of 2020. Four strategic goals still fit for purpose:
a. To advocate for people with Parkinson's and their families to get the right information at the right time throughout their Parkinson's journey.
b. To strive for healthcare systems where people with Parkinson's receive early and appropriate treatment and individualised care.
c. To raise awareness of the complexity of Parkinson's and the impact it has on people's quality of life.
Page 1
**European Parkinson's Disease Association**
## **Report of the Trustees**
## **for the Year Ended 31st December 2020**
d. To support the global Parkinson's community in the search for a cure.
Three new strategic themes for the next three years:
a. Uniting Europe
b. Big data c. Research
## **Membership**
Three new member organisations approved by the AGM in 2020 Member's survey
o Most member organisations are 'satisfied' with being EPDA members
o Most member organisations think the EPDA six-year strategy is fit for purpose
o Most member organisations think the current level of communication with the EPDA is 'good' or 'excellent'
Completion of a set of guidelines aimed at Parkinson's organisations in the event of a shortage of medicines (this idea was initiated as a result of the panel discussion at the 2019 Members' Meeting)
Involvement of 18 member organisations in the WPC clinical trials survey, and eight in the subsequent in-depth conference calls
Members' Meeting 2020 (virtual): participation and engagement from 20 members Member-specific activities being planned for 2021:
o Exclusive EPDA member virtual roundtable events
o EPDA membership grant scheme
## **Results**
o Improved two-way communication between EPDA and MOs
o Development of EPDA-members partnered activities on topics that are fundamental for the European Parkinson's community
The EPDA would be delighted to hear about any initiatives from our members and partners that we could support, help advertise and promote, or advise on. If you need any help, please do get in touch and ask us!
## **Team improvements**
A new Project Manager A new Communications Lead
Team restructuring: increasing hours and streamlining roles and tasks for all Team members
## **Results**
o Improved expertise within the Team o Smoother internal functioning
## **EPDA exposure**
High-profile international congresses:
o Continued partnership and collaboration with WPC 2022, which will lead to very exciting EPDA-led activities in 2021 and 2022
o MDS 2020: presentation of abstract about the EPDA-Air Liquide survey on the challenges of Parkinson's carers o INSIGHT into Parkinson's 2020: presentation on the EPDA survey on the challenges of Parkinson's carers
Medical/scientific journals:
o Advertisements and highlights from our website and the Parkinson's Disease Composite Scale (Oruen, touchNeurology)
## **Results**
Increased knowledge and awareness of the EPDA and Parkinson's in the medical/scientific community Increased knowledge and awareness of the EPDA work in the Parkinson's community
## **Treatment industry collaboration**
Funding (including work done in 2020 that has led to partnerships in 2021). Note: details below correct as at 8 February 2021
o Diamond partners: AbbVie (2020)
Page 2
**European Parkinson's Disease Association**
## **Report of the Trustees**
## **for the Year Ended 31st December 2020**
Boston Scientific (2020 and 2021) Britannia Pharmaceuticals (2021) Kyowa Kirin (2021) Sunovion (2020 and 2021) o Gold partners: Abbott (2021) Air Liquide (2020 and 2021) BIAL (2020 and 2021) Medtronic (2020 and 2021) Merz (2020 and 2021) Servier (2021) UCB (2020) o Silver partners: Biogen (2021) EverPharma (2020) Servier (2020) Theravance Biopharma (2021) UCB (2021) Zambon (2020 and 2021) o Tech partners: GE Healthcare (2020) Insightec (2020) o Other partners: Herantis (2020) Lundbeck (2020)
Partnered projects include:
o **Abbott:** development of a content campaign to raise awareness of the DBS options available to people with Parkinson's o **AbbVie:** EPDA Board members supporting AbbVie in the development of its Parkinson's research investigations o **Air Liquide:** carers' survey (dissemination of results in 2020 and 2021)
o **Bial:** collaboration with BIAL on the Keep it ON video awareness campaign, developing a series of awareness videos involving people with Parkinson's from five European countries o **Bial:** development of the Keep ON Moving! dual-task video exercise project in collaboration with BIAL
o **Britannia Pharmaceuticals** : development of a content campaign to raise awareness of the non-oral treatment options available to people with Parkinson's
o **Herantis and TreatER:** EU-funded project concluded and results published in a virtual webinar held in November 2020 o **Kyowa Kirin:** participation of the EPDA in an advisory panel on patient organisations engagement organised by Kyowa Kirin
o **Medtronic:** support of Medtronic's new Percept device launch, and review of World Parkinson's Day awareness materials o **Merz:** survey on sialorrhea in Parkinson's developed in collaboration with Merz (carried out in 2020, results expected in 2021)
o **Servier:** organisation of a workshop with people with Parkinson's, carers and advocates (preparation in 2020, virtual workshop to be held in 2021) in collaboration with Servier
o **Sunovion:** awareness communication campaign on Sunovion's clinical trial of sublingual apomorphine - developed in 2020, to be launched in early 2021
## **Results**
Increased participation of the Parkinson's community (represented by the EPDA) in industry activities Ultimately, the development of better treatment, support and care solutions for people with Parkinson's
## **Research**
TreatER project o Long-time collaboration with Herantis Pharma and lead academic universities o Started in 2017
o Results presented at a virtual scientific conference in November 2020
Sunovion CTH-302 trial
o Collaboration with treatment company and research institutions in six European countries
Page 3
**European Parkinson's Disease Association**
## **Report of the Trustees**
## **for the Year Ended 31st December 2020**
o Raising awareness of the clinical trial opportunities available to the Parkinson's community
Servier clinical trial design
o Involving the Parkinson's community in the guiding, planning, design and development of Servier's upcoming clinical trial o Organisation of a collaborative workshop with people with Parkinson's, carers and patient advocates
WPC clinical trials interest group
o Working with Parkinson's associations from around the world on surveys and conference calls in order to gather information about the barriers and opportunities for Parkinson's communities interested in getting involved in research
## **Results**
Increased involvement of the Parkinson's community (represented by the EPDA, EPDA members and Parkinson's advocates) in the planning and design of treatment research More inclusive, effective and patient-friendly clinical trials
Ultimately, the development of better treatment solutions for people with Parkinson's
## **Advocacy**
2020 was the year to prepare the ground for the EPDA's outreach for the next four years. A new EU came into power in 2020 and we have been assessing how they view health and indeed whether they know about Parkinson's. We are completing an in-depth political mapping of who's who in the Institutions directly but also indirectly influencing/impacting health policy. We have undertaken a decision-makers survey to assess their understanding of the disease and we have reached out to them to both introduce ourselves and to lay out our needs and asks.
We have developed a number of hooks for future advocacy campaigning in EU-Brussels around the role of carers as a follow-up to the EPDA/Air Liquide survey; around the role of pesticides and their impact on Parkinson's, and most recently on the EU's review of the pharmaceutical industry which will be a on-going issue for the year to come, looking at, for example, equal access to medicines, shortages of medicines, and many other key topics
The EPDA has been engaged closely with EFNA and played a role in developing their strategy for the Brain, Mind and Pain EP intergroup
We have developed the EU-Brussels Political Advocacy bi-monthly newsletter aimed at member organisations and other EPDA stakeholders
Ongoing support to the PD Avengers advocacy group throughout 2020 and into 2021
## **Results**
Increased awareness of the complexity of Parkinson's and the impact it has on people's quality of life Ultimately, better policies and public interventions in support of people with Parkinson's, their families and carers
## **Resources and digital communication**
Sleep and Parkinson's awareness campaign: initiated in Q4 2020 and to be launched in 2021 EPDA Exercise Cast: our own online video exercise series for people with Parkinson's (which led directly to the incredibly successful Keep ON Moving! exercise video series we created in collaboration with our partner, Bial) #BrainLifeGoals: educational video for HCPs focusing on cognitive-motor exercise programmes
## **EPDA website**
o Nearly 370,000 users and more than 850,000 page views o Traffic from more than 200 countries
o High engagement to the About Parkinson's and Living Well sections
## **Parkinson's Life**
o Parkinson's Life podcast awarded 'Best Global Audio Campaign of the Year' at the Global Content Awards 2020 o Nearly 270,000 users and 400,000 page views
EPDA strategic communications review - initiated in 2020, due to be finalised and implemented in 2021
## **Results**
o Increased awareness of the complexity of Parkinson's and the impact it has on people's quality of life o Delivery of high-quality information and resources to the Parkinson's community
Page 4
**European Parkinson's Disease Association**
## **Report of the Trustees**
## **for the Year Ended 31st December 2020**
## **FINANCIAL REVIEW**
## **Going concern**
At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.
The Association's reserve policy is to hold reserves only to cover a period of 6 months administration costs. No additional reserves are intended to be held. Further analysis of restricted and unrestricted funds can be found in note 14.
## **STRUCTURE, GOVERNANCE AND MANAGEMENT**
The charity was established by a charitable trust deed on 25th April 1998 in Belgium and registered as a Charitable Incorporated Organisation in the UK on 19th August 2015.
The trustees have had regard to the Charity Commission's guidance on public benefit.
## **REFERENCE AND ADMINISTRATIVE DETAILS Registered Company number**
CE004367 (England and Wales)
## **Registered Charity number**
1163211
## **Registered office**
Kings Lodge London Road West Kingsdown Sevenoaks Kent TN15 6AR
## **Trustees**
Mr K Onarheim (resigned 1.9.20) Ms M E Graham Ms S Lindvall (resigned 1.9.20) Ms V Clark Mr D J Lavender MBE Ms V A Buxton Ms P Gilmore J Domingos (appointed 1.9.20) C P Likar (appointed 1.9.20) T Shaish (appointed 1.9.20)
## **Independent Examiner**
A4G LLP Kings Lodge London Road West Kingsdown Sevenoaks Kent TN15 6AR
Approved by order of the board of trustees on ............................................. and signed on its behalf by:
.................................................................... Ms V Clark - Trustee
Page 5
## **Independent Examiner's Report to the Trustees of European Parkinson's Disease Association**
## **Independent examiner's report to the trustees of European Parkinson's Disease Association ('the Company')**
I report to the charity trustees on my examination of the accounts of the Company for the year ended 31st December 2020.
## **Responsibilities and basis of report**
As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').
Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.
## **Independent examiner's statement**
Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a registered member of ACA which is one of the listed bodies.
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:
1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
Caroline Coleman ACA A4G LLP Kings Lodge London Road West Kingsdown Sevenoaks Kent TN15 6AR
Date: .............................................
Page 6
**European Parkinson's Disease Association**
## **Statement of Financial Activities**
## **(Incorporating an Income and Expenditure Account) for the Year Ended 31st December 2020**
|Unrestricted
funds
Notes
£
**INCOME AND ENDOWMENTS FROM**
Donations and legacies
4
28,283
**Charitable activities**
5
Member organisaton and board meetings
-
Other income
-
Investments
174
Publications
-
Project Income
-
Core Income
352,597
**Total**
381,054
**EXPENDITURE ON**
**Charitable activities**
6
Member organisaton and board meetings
22,762
Advocacy communication and project development
213,615
Grant Funded projects
67,809
Support costs
186,018
Governance costs
1,000
Other
1,326
**Total**
492,530
Net gains/(losses) on investments
3,213
**NET INCOME/(EXPENDITURE)**
(108,263)
**RECONCILIATION OF FUNDS**
**Total funds brought forward**
119,912
**TOTAL FUNDS CARRIED FORWARD**
11,649|Restricted
funds
£
-
-
-
-
-
-
178,911
178,911
-
5,505
10,299
11,334
-
-
27,138
(10,942)
140,831
182,767
323,598|2020
Total
funds
£
28,283
-
-
174
-
-
531,508
559,965
22,762
219,120
78,108
197,352
1,000
1,326
519,668
(7,729)
32,568
302,679
335,247|2019
Total
funds
£
26,626
22,374
1,895
313
6,774
52,557
255,664
366,203
40,223
72,356
100,025
129,098
1,000
-
342,702
(2,285)
21,216
281,463
302,679|
|---|---|---|---|
The notes form part of these financial statements
Page 7
**European Parkinson's Disease Association**
## **Statement of Financial Position**
## **31st December 2020**
|Notes
**CURRENT ASSETS**
Debtors
11
Cash at bank and in hand
**CREDITORS**
Amounts falling due within one year
12
**NET CURRENT ASSETS**
**TOTAL ASSETS LESS CURRENT LIABILITIES**
**NET ASSETS**
**FUNDS**
14
Unrestricted funds
Restricted funds
**TOTAL FUNDS**|2020
£
133,500
457,222
590,722
(255,475)
335,247
335,247
335,247
11,650
323,597
335,247|2019
£
68,704
411,317
480,021
(177,342)
302,679
302,679
302,679
119,912
182,767
302,679|
|---|---|---|
The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st December 2020.
The members have not required the company to obtain an audit of its financial statements for the year ended 31st December 2020 in accordance with Section 476 of the Companies Act 2006.
## The trustees acknowledge their responsibilities for
(a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.
The financial statements were approved by the Board of Trustees and authorised for issue on ............................................. and were signed on its behalf by:
............................................. Ms V Clark - Trustee
............................................. Mr D J Lavender MBE - Trustee
The notes form part of these financial statements
Page 8
**European Parkinson's Disease Association**
## **Statement of Cash Flows**
## **for the Year Ended 31st December 2020**
|Notes
**Cash flows from operating activities**
Cash generated from operations
1
Net cash provided by operating activities
**Cash flows from investing activities**
Sale of fixed asset investments
Net cash used in investing activities
**Change in cash and cash equivalents in**
**the reporting period**
**Cash and cash equivalents at the**
**beginning of the reporting period**
**Cash and cash equivalents at the end of**
**the reporting period**|2020
£
53,634
53,634
(7,729)
(7,729)
45,905
411,317
457,222|2019
£
28,365
28,365
(2,285)
(2,285)
26,080
385,237
411,317|
|---|---|---|
The notes form part of these financial statements
Page 9
**European Parkinson's Disease Association**
## **Notes to the Statement of Cash Flows**
## **for the Year Ended 31st December 2020**
|**1.**|**RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING**|**RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING**|**ACTIVITIES**||
|---|---|---|---|---|
||||2020|2019|
||||£|£|
||**Net income for the reporting period (as per the Statement of**||||
||**Financial Activities)**||32,568|21,216|
||**Adjustments for:**||||
||Losses on investments||7,729|2,285|
||(Increase)/decrease in debtors||(64,796)|20,936|
||Increase/(decrease) in creditors||78,133|(16,072)|
||**Net cash provided by operations**||53,634|28,365|
|2.|**ANALYSIS OF CHANGES IN NET FUNDS**||||
|||At 1.1.20|Cash flow|At 31.12.20|
|||£|£|£|
||**Net cash**||||
||Cash at bank and in hand|411,317|45,905|457,222|
The notes form part of these financial statements
Page 10
**European Parkinson's Disease Association**
## **Notes to the Financial Statements**
## **for the Year Ended 31st December 2020**
## **1. CHARITY INFORMATION**
European Parkinson's Disease Association is a Charitable Incorporated Organisation registered in the UK on 19 August 2015.
## **2. ACCOUNTING POLICIES**
## **Accounting convention**
The accounts have been prepared in accordance with the charity's trust deed, the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and “Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)” (as amended for accounting periods commencing from 1 January 2016). The charity is a Public Benefit Entity as defined by FRS 102.
The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.
The financial statements are prepared in sterling , which is the functional currency of the charity. Monetary a mounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.
## **Incoming resources**
Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.
Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.
Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.
Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods and services provided in the normal course of business, net of discounts, VAT and other sales related taxes.
## **Charitable funds**
Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.
Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.
Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.
## **Financial instruments**
The charity has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.
continued...
Page 11
**European Parkinson's Disease Association**
## **Notes to the Financial Statements - continued**
**for the Year Ended 31st December 2020**
## **2. ACCOUNTING POLICIES - continued**
## **Financial instruments**
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
## **Basic financial assets**
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
## **Basic financial liabilities**
Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
## **Derecognition of financial liabilities**
Financial liabilities are derecognised when the charity’s contractual obligations expire or are discharged or cancelled.
## **Employee benefits**
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
## **Foreign exchange**
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation are included in net income/(expenditure for the period.
## **Leases**
Rentals payable under operating leases, including any lease incentives received, are charged as an expense on a straight line basis over the term of the relevant lease.
## **Irrecoverable vat**
Irrecoverable VAT is charged against the expenditure heading for which it was incurred.
continued...
Page 12
**European Parkinson's Disease Association**
## **Notes to the Financial Statements - continued**
## **for the Year Ended 31st December 2020**
## **3. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY**
In the application of the charity’s accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
## **4. DONATIONS AND LEGACIES**
|Members fees
Donations
**5.**
**INCOME FROM CHARITABLE ACTIVITIES**
Member organisation meeting
Other income
Investments
Publication income
Project income
Core income|2020
£
23,904
4,379
28,283
2020
£
-
-
174
-
-
531,508
531,682|2019
£
24,408
2,218
26,626
2019
£
22,374
1,895
313
6,774
52,557
255,664
339,577|
|---|---|---|
## **6. CHARITABLE ACTIVITIES COSTS**
|Member organisaton and board meetings
Advocacy communication and project
development
Grant Funded projects
Support costs
Governance costs|Direct
Costs
£
22,762
215,978
78,108
68,988
-
385,836|Support
costs (see
note 7)
£
-
3,142
-
128,364
1,000
132,506|Totals
£
22,762
219,120
78,108
197,352
1,000
518,342|
|---|---|---|---|
continued...
Page 13
**European Parkinson's Disease Association**
## **Notes to the Financial Statements - continued**
## **for the Year Ended 31st December 2020**
## **7. SUPPORT COSTS**
|Management
£
Advocacy communication and
project development
3,142
Support costs
5,637
Governance costs
-
8,779
Support costs, included in the above, are as follows:
Advocacy
communication
and
project
development
£
Advertising
3,142
Fundraising
-
Wages
-
Bank charges
-
Financial administration
-
Accountancy fees
-
Bookkeeping costs
-
General expenditure
-
Administration costs
-
Independent examination
costs
-
3,142|Governance
Finance
Other
costs
£
£
£
-
-
-
65,095
57,632
-
-
-
1,000
65,095
57,632
1,000
2020
Support
Governance
Total
costs
costs
activities
£
£
£
-
-
3,142
5,637
-
5,637
25,099
-
25,099
178
-
178
30,818
-
30,818
5,000
-
5,000
4,000
-
4,000
12,714
-
12,714
44,918
-
44,918
-
1,000
1,000
128,364
1,000
132,506|Totals
£
3,142
128,364
1,000
132,506
2019
Total
activities
£
-
14,926
8,693
-
15,326
4,760
-
13,062
8,436
1,000
66,203|
|---|---|---|
Support costs, included in the above, are as follows:
## **8. TRUSTEES' REMUNERATION AND BENEFITS**
Ms M E Graham received fees totalling £24,703 (2019: £16,747) in connection with her role as strategic advisor. The payments have been made in accordance with the charity's constitution and approved by the other trustees.
## **9. STAFF COSTS**
|Wages and salaries|2020
£
25,099
25,099|2019
£
8,693
8,693|
|---|---|---|
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
The average monthly number of employees during the year was as follows:
||2020|2019|
|---|---|---|
|Administration|2|2|
continued...
Page 14
**European Parkinson's Disease Association**
## **Notes to the Financial Statements - continued**
## **for the Year Ended 31st December 2020**
## **9. STAFF COSTS - continued**
The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:
|£60,001 - £70,000
**10.**
**COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**
Unrestricted
funds
£
**INCOME AND ENDOWMENTS FROM**
Donations and legacies
26,628
**Charitable activities**
Member organisaton and board meetings
22,374
Other income
1,895
Investments
313
Publications
6,774
Project Income
39,316
Core Income
174,249
**Total**
271,549
**EXPENDITURE ON**
**Charitable activities**
Member organisaton and board meetings
40,223
Advocacy communication and project
development
72,356
Grant Funded projects
4,200
Support costs
126,880
Governance costs
1,000
**Total**
244,659
Net gains/(losses) on investments
(2,285)
**NET INCOME/(EXPENDITURE)**
24,605
**RECONCILIATION OF FUNDS**
**Total funds brought forward**
95,309
**TOTAL FUNDS CARRIED FORWARD**
119,914|2020
1
Restricted
funds
£
(2)
-
-
-
-
13,241
81,415
94,654
-
-
95,825
2,218
-
98,043
-
(3,389)
186,154
182,765|2019
-
Total
funds
£
26,626
22,374
1,895
313
6,774
52,557
255,664
366,203
40,223
72,356
100,025
129,098
1,000
342,702
(2,285)
21,216
281,463
302,679|
|---|---|---|
continued...
Page 15
**European Parkinson's Disease Association**
## **Notes to the Financial Statements - continued**
|**for the Year Ended 31st December 2020**
**11.**
**DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**
Trade debtors
Prepayments and accrued income
**12.**
**CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**
Trade creditors
Social security and other taxes
Net wages
Pension
Accruals and deferred income
**13.**
**ANALYSIS OF NET ASSETS BETWEEN FUNDS**
Unrestricted
funds
£
Current assets
267,125
Current liabilities
(255,475)
11,650|Restricted
funds
£
323,597
-
323,597|2020
£
120,397
13,103
133,500
2020
£
68,718
1,878
7,769
255
176,855
255,475
2020
Total
funds
£
590,722
(255,475)
335,247|2019
£
68,477
227
68,704
2019
£
43,913
5,637
5,568
256
121,968
177,342
2019
Total
funds
£
480,021
(177,342)
302,679|
|---|---|---|---|
continued...
Page 16
**European Parkinson's Disease Association**
## **Notes to the Financial Statements - continued**
## **for the Year Ended 31st December 2020**
## **14. MOVEMENT IN FUNDS**
|**Unrestricted funds**
General fund
Parkinson's Life
**Restricted funds**
PDCS
Research/Clinical trials
Parkinson's Information
Data Collection
Treat ER
European Young Onset PD
Advanced therapies
AirLiquide Carers Project
Brain Life Goals
Bial
HCP Info/Educational Materials
Parkinson Sleep Project
Parkinson's Games
Tshipi's Art Exhibition
WPC Barcelona 2020
**TOTAL FUNDS**|Net
movement
At 1.1.20
in funds
£
£
124,112
(112,551)
(4,200)
4,289
119,912
(108,262)
30,637
7,814
-
34,008
7,487
(7,487)
12,498
(131)
91,752
(4,046)
40,393
462
-
13,103
-
25,665
-
2,529
-
12,091
-
8,786
-
27,252
-
3,186
-
3,043
-
14,555
182,767
140,830
302,679
32,568|At
31.12.20
£
11,561
89
11,650
38,451
34,008
-
12,367
87,706
40,855
13,103
25,665
2,529
12,091
8,786
27,252
3,186
3,043
14,555
323,597
335,247|
|---|---|---|
continued...
Page 17
**European Parkinson's Disease Association**
## **Notes to the Financial Statements - continued**
## **for the Year Ended 31st December 2020**
## **14. MOVEMENT IN FUNDS - continued**
Net movement in funds, included in the above are as follows:
|**Unrestricted funds**
General fund
Parkinson's Life
**Restricted funds**
PDCS
Research/Clinical trials
Parkinson's Information
Data Collection
Treat ER
European Young Onset PD
Advanced therapies
AirLiquide Carers Project
Brain Life Goals
Bial
HCP Info/Educational Materials
Parkinson Sleep Project
Parkinson's Games
Tshipi's Art Exhibition
WPC Barcelona 2020
**TOTAL FUNDS**|Incoming
resources
£
315,855
65,200
381,055
9,804
37,339
2,247
-
-
2,693
13,103
29,731
2,705
15,721
9,035
29,418
4,260
3,361
19,493
178,910
559,965|Resources
expended
£
(424,721)
(67,809)
(492,530)
(1,992)
(3,331)
(2,836)
(131)
-
(2,231)
-
(4,066)
(176)
(3,630)
(249)
(2,166)
(1,074)
(318)
(4,938)
(27,138)
(519,668)|Gains and
Movement
losses
in funds
£
£
(3,685)
(112,551)
6,898
4,289
3,213
(108,262)
2
7,814
-
34,008
(6,898)
(7,487)
-
(131)
(4,046)
(4,046)
-
462
-
13,103
-
25,665
-
2,529
-
12,091
-
8,786
-
27,252
-
3,186
-
3,043
-
14,555
(10,942)
140,830
(7,729)
32,568|
|---|---|---|---|
## **Comparatives for movement in funds**
|**Unrestricted funds**
General fund
Parkinson's Life
**Restricted funds**
PDCS
Parkinson's Information
Data Collection
Treat ER
European Young Onset PD
**TOTAL FUNDS**|Net
movement
At 1.1.19
in funds
£
£
95,309
28,803
-
(4,200)
95,309
24,603
51,115
(20,478)
1,168
6,319
12,498
-
91,752
-
29,621
10,772
186,154
(3,387)
281,463
21,216|At
31.12.19
£
124,112
(4,200)
119,912
30,637
7,487
12,498
91,752
40,393
182,767
302,679|
|---|---|---|
continued...
Page 18
**European Parkinson's Disease Association**
## **Notes to the Financial Statements - continued**
## **for the Year Ended 31st December 2020**
## **14. MOVEMENT IN FUNDS - continued**
Comparative net movement in funds, included in the above are as follows:
|**Unrestricted funds**
General fund
Parkinson's Life
**Restricted funds**
PDCS
Parkinson's Information
European Young Onset PD
Advanced therapies
AirLiquide Carers Project
Parkinson’s Life
**TOTAL FUNDS**|Incoming
resources
£
271,547
-
271,547
-
8,696
13,103
13,103
2,444
57,310
94,656
366,203|Resources
expended
£
(240,459)
(4,200)
(244,659)
(20,478)
(2,377)
(2,331)
(13,103)
(2,444)
(57,310)
(98,043)
(342,702)|Gains and
Movement
losses
in funds
£
£
(2,285)
28,803
-
(4,200)
(2,285)
24,603
-
(20,478)
-
6,319
-
10,772
-
-
-
-
-
-
-
(3,387)
(2,285)
21,216|
|---|---|---|---|
## **15. RELATED PARTY DISCLOSURES**
There were no related party transactions for the year ended 31st December 2020.
Page 19
**European Parkinson's Disease Association**
|**Detailed Statement of Financial Activities**
**for the Year Ended 31st December 2020**
**INCOME AND ENDOWMENTS**
**Donations and legacies**
Members fees
Donations
**Charitable activities**
Member organisation meeting
Publication income
Investments
Other income
Core income
Project income
**Total incoming resources**
**EXPENDITURE**
**Charitable activities**
Members meeting
Administration Board
PDG think tank
Website
Parkinson’s life
Exhibitions
Communications
Social media
Digital strategy
Member organisation outreach
GDPR
PDCS
Research/clinical trials
Parkinson's info
Data collection
Global campaign
Treat ER
EYOPD
Advocacy
AirLiquide carers project
Adviser
Prevalence
Merz (survey/HCP awareness)
Medtronic Awareness projects
HCP info/education materials
Carried forward|2020
£
23,904
4,379
28,283
-
-
174
-
531,508
-
531,682
559,965
7,246
22,105
-
9,690
72,009
1,539
14,185
6,629
6,083
10,273
540
2,946
3,331
2,836
131
-
8,220
2,231
161,744
4,066
16,194
302
3,017
309
249
355,875|2019
£
24,408
2,218
26,626
22,374
6,774
313
1,895
255,664
52,557
339,577
366,203
38,052
31,991
2,171
7,922
58,392
12,999
10,050
20,470
10,228
11,934
1,076
28,089
1,550
2,748
1,812
2,404
250
2,380
1,877
28,557
1,547
-
-
-
-
276,499|
|---|---|---|
This page does not form part of the statutory financial statements
Page 20
**European Parkinson's Disease Association**
## **Detailed Statement of Financial Activities for the Year Ended 31st December 2020**
|**Charitable activities**
Brought forward
Awareness campaigns
Brain life goals
Bial's
Servier patient insights works
Kyowa kirin
Abbott
AbbVie
Boston affiliates
Britannia (awareness)
CMS
EPDA industry meeting
Industry partnered projects
Medtronic partnered project
NeuroPath EU project
Parkinson sleep project
Parkinson's games
Sunovion research project
Tshipi's art exhibition
WPC Barcelona
**Other**
Rent
**Support costs**
**Management**
Advertising
Fundraising
**Finance**
Wages
Bank charges
Financial administration
Accountancy fees
Bookkeeping costs
**Other**
General expenditure
Administration costs
**Governance costs**
Independent examination costs|2020
£
355,875
2,202
176
3,630
2,838
289
39
228
18
507
2,208
2,048
3,177
147
612
2,166
1,074
3,346
318
4,938
385,836
1,326
3,142
5,637
8,779
25,099
178
30,818
5,000
4,000
65,095
12,714
44,918
57,632
1,000|2019
£
276,499
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
276,499
-
-
14,926
14,926
8,693
-
15,326
4,760
-
28,779
13,062
8,436
21,498
1,000|
|---|---|---|
This page does not form part of the statutory financial statements
Page 21
**European Parkinson's Disease Association**
|**Detailed Statement of Financial Activities**
**for the Year Ended 31st December 2020**
Total resources expended
**Net income before gains and losses**
**Realised recognised gains and losses**
Realised gains/(losses) on fixed asset investments
**Net income**|2020
£
519,668
40,297
(7,729)
32,568|2019
£
342,702
23,501
(2,285)
21,216|
|---|---|---|
This page does not form part of the statutory financial statements
Page 22
**European Parkinson's Disease Association**
## **Statement of Financial Activities for**
## **the Year Ended 31st December 2020**
|**INCOME AND ENDOWMENTS**
**Donations**
Members Fees
Donations
**Charitable Activities**
Member organisation meeting
Publication Income
Investments
Other income
Core income
Project income
**Total incoming resources**
**EXPENDITURE**
**Charitable activities**
Members meeting
Administration Board
PDG think tank
Website
Parkinson’s life
Exhibitions
Communications
Social Media
Digital strategy
Member organisation outreach
GDPR
PDCS
Research/clinical trials
Parkinson’s info
Data collection
Global campaign
Treat ER
EYOPD
Advocacy
AirLiquide carers project
Adviser
Prevalence
Merz (survey/HCP awareness)
Medtronic Awareness projects
HCP info/education materials
Carried forward|**2020(£)**|**2020(£)**|**2020(€)**|**2020(€)**|**2019(£)**|**2019(£)**|**2019(€)**|
|---|---|---|---|---|---|---|---|
||
|23,904
4,379
28,283
-
-
174
-
531,508
-
531,682
559,965
7,246
22,105
-
9,690
72,009
1,539
14,185
6,629
6,083
10,273
540
2,946
3,331
2,836
131
-
8,220
2,231
161,744
4,066
16,194
302
3,017
309
249
355,875|
|26,709
4,893
31,602
-
-
194
-
593,882
-
594,077
625,679
8,096
24,699
2,566
10,827
80,460
1,720
15,850
7,407
6,797
11,479
603
3,292
3,720
3,169
146
-
9,185
2,493
180,725
4,543
18,094
337
3,371
345
278
397,638||24,408
2,218
26,626
22,374
6,774
313
1,895
255,664
52,557
339,577
366,203
38,052
31,991
2,171
7,922
58,392
12,999
10,050
20,470
10,228
11,934
1,076
28,089
1,550
2,748
1,812
2,404
250
2,380
1,877
28,557
1,547
-
-
-
-
276,499||
This page does not form part of the statutory financial statements
Page 23
**European Parkinson's Disease Association**
## **Statement of Financial Activities for**
## **the Year Ended 31st December 2020**
|**Charitable activities**
Brought forward
Awareness campaigns
Brain life goals
Bial's
Servier patient insights works
Kyowa kirin
Abbott
AbbVie
Boston affiliates
Britannia (awareness)
CMS
EPDA industry meeting
Industry partnered projects
Medtronic partnered project
NeuroPath EU project
Parkinson sleep project
Parkinson's games
Sunovion research project
Tshipi's art exhibition
WPC Barcelona
**Other**
Rent
**Support costs**
**Management**
Advertising
Fundraising
**Finance**
Wages
Bank charges
Financial administration
Accountancy fees
Bookkeeping costs
**Other**
General expenditure
Administration costs
**Governance costs**
Independent examination costs||
|355,875
2,202
176
3.630
2,838
289
39
228
18
507
2,208
2,048
3,177
147
612
2,166
1,074
3,346
318
4,938
385,836
1,326
3,142
5,637
8,779
25,099
178
30,818
5,000
4,000
65,095
12,714
44,918
57,632
1,000|
|397,638
2,460
197
4,056
3,171
323
44
255
20
566
2,467
2,288
3,550
164
684
2,420
1,200
3,739
355
5,517
431,115
1,482
3,511
6,299
9,809
28,044
199
34,435
5,587
4,469
72,734
14,206
50,189
64,395
1,117|276,499
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
276,499
-
-
-
-
8,693
-
15,326
4,760
-
28,779
13,062
8,436
21,498
1,000|326,753
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
326,753
-
-
-
-
10,273
-
18,112
5,625
-
34,010
15,436
9,969
25,405
1,182|
|---|---|---|---|---|---|---|---|
|||
||||||
|||
|||||
|
|||
||||||
This page does not form part of the statutory financial statements
Page 24
**European Parkinson's Disease Association**
## **Statement of Financial Activities for**
## **the Year Ended 31st December 2020**
|Total resources expended
**Net income before gains and losses**
**Realised recognised gains and losses**
Realised gains/(losses) on fixed asset investments
**Net income**|
|519,668
40,297
(7,729)
32,568|
|580,653
45,026
(8,636)
36,390|
|342,702
23,501
(2,285)
21,216|
|404,988
27,772
(2,700)
25,072|
|---|---|---|---|---|---|---|---|---|
||
||
||
||
||
This page does not form part of the statutory financial statements
Page 25
**European Parkinson's Disease Association**
## **Statement of Financial Position for**
## **the Year Ended 31st December 2020**
|**Statement of Financial Position for**
**the Year Ended 31st December 2020**|||||||||
|---|---|---|---|---|---|---|---|---|
|**CURRENT ASSETS**
Debtors
Cash at bank and in hand
**CREDITORS**
Amounts falling due within one year
**NET CURRENT ASSETS**
**TOTAL ASSETS LESS CURRENT LIABILITIES**
**NET ASSETS**
**FUNDS**
Unrestricted funds
Restricted funds
**TOTAL FUNDS**||**2020(£)**|**2020(€)**||**2019(£)**||**2019(€)**||
|||133,500
457,222
590,722
(255,475)
335,247
335,247
11,650
323,597
335,247|149,167
510,879
660,045
(285,456)
374,589
374,589
13,017
361,572
374,589|149,167
510,879|
|68,704
411,317||81,191
486,074
567,265
(209,574)
357,691
357,691
146,669
211,022
357,691|
|||||374,589
13,017
361,572|||||
|||||
374,589|||||
This page does not form part of the statutory financial statements
Page 26